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Abstract 
 Histone deacetylases (HDACs) have become one of the leading areas of research 
for cancer, neurodegenerative diseases, diabetes, obesity, and inflammation.  Although 
HDACs are currently expressible in mammalian cultures and yeast, it is important to 
explore other cost effective options.  Here it is shown that class I HDACs are expressible 
in insect cells.  As well as expressing full length domains for class I HDACs, predicted 
active domains have also been expressed.  This information can be utilized in many areas 
for future research including identifying unique sites to allow development of specific 
inhibitors for each HDAC, and developing a better understanding of the specific role of 
each HDAC.    
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1.0 Introduction: 
 DNA packaging is important in the regulation of transcription.  When cells are in 
a resting state DNA is compacted tightly into a DNA-protein complex called chromatin.  
This structure is tightly put together to protect it from the binding of transcription factors 
and allow the compaction of the long genome into the smaller nuclear compartment.  
Chromatin’s main subunit is the nucleosome which is made up of an octamer of core 
histones consisting of a H3-H4 histone tetramer and two H2A-H2B histone dimers, all 
wrapped in 146 bp DNA (De Ruijter et al., 2003; Hassig and Schreiber, 1997).  When 
gene transcription is activated the chromatin relaxes and transcription factors are able to 
bind the DNA.  Changes to the chromatin structure by acetylating the core histones can 
facilitate gene expression.  The acetylation is carried out by histone acetyltransferases 
(HATs); this decreases the interaction between DNA and histone proteins.  Histone 
deacetylases (HDACs) remove acetyl groups, increasing DNA and histone interactions.  
The nature of the DNA-histone interaction will determine how well transcription factors 
can bind to the DNA. 
1.1 Class information 
Currently, eleven HDACs have been identified and placed within separate classes 
based on phylogenetic characteristics.  Class I consists of HDACs 1, 2, 3, and 8 and is 
similar to the yeast protein Rpd3; Class II consists of HDACs 4, 5, 6, 7, 9, and 10 and is 
related to the yeast protein Hdalp; and HDAC 11 has recently been placed into its own 
class, Class IV (Wang et al., 2005).  There is also a Class III that consists of sirtuin 
deacetylases, which are related to the yeast protein Sir2 (Gregoretti et al., 2004).  The 
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separation of HDACs into these separate classes is based on sequence similarities.  For 
example, the DNA sequence similarity for class I HDACs is 75% for HDAC1 and 2, 50% 
for HDAC1 and 3, and finally 51% similarity between HDAC2 and 3.    
Although eleven HDACs have been identified, only HDAC8 has been 
crystallized.  As scientists try to characterize the other ten HDACs, they will be using the 
information on HDAC8s structure, as well as possible structures and functions of the 
other HDACs and applying them to one another.  For example, because the classes have 
already been distinguished based on a phylogenetic analysis then HDAC8 can be 
compared to HDACs 1, 2, and 3 because of the many similarities.  When attempting to 
use information that is already known about one HDAC and apply it to another it is best 
to know whether those HDACs are “paralogs” or “orthologs” of one another.  It is 
expected that paralogs will be functionally different, while orthologs will have similar 
functions and characteristics (Gegoretti et al., 2004).   
The information currently known about the separate classes of HDACs identifies 
the first class as being found exclusively in the nucleus and expressed in various immune 
tissues, while Class II HDACs appear to be located in both the nucleus and cytoplasm 
and are more tissue specific and associated with muscle function (Blanchard and Chipoy, 
2005; Gregoretti et al., 2004).  Although there appear to be separate functions for each 
class of HDACs as well as each HDAC itself, there is interaction between HDACs from 
different classes.  This can be seen with HDAC3, a class I HDAC, which interacts with 
many class II HDACs including HDACs 4, 5, and 10 (De Ruijter et al., 2003).  HDAC3 
has both a nuclear import signal and a nuclear export signal, while HDAC1, 2, and 8 only 
have a nuclear import signal.  These signals allow HDAC3 to be recruited by class II 
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HDACs and form oligomers with them with the assistance of the co-repressors: silencing 
mediator for retinoid and thyroid hormone receptors (SMRT) and nuclear receptor co-
repressors (N-CoR) (De Ruijter et al., 2003).   
1.2 Acetylation effects  
As previously mentioned histone acetylation and deacetylation have been shown 
to be linked to transcriptional regulation (Hassig and Schreiber, 1997).  Acetylation 
weakens the histone-DNA interactions by neutralizing the positive charge on the lysine 
residues.  This reduces the attraction between the histone tail and the negatively charged 
DNA.  When the DNA-histone interaction weakens there is more access to DNA binding 
sites by transcription factors and possibly DNA replication factors.  Histone deacetylases 
can suppress transcription and reduce DNA replication by deacetylating chromatin and 
allowing ionic interaction between the histone lysines and the phosphates on DNA (Fig. 
1).  
 
 
1.3 HDAC complexes 
 HDACs appear in many different protein complexes.  The mSin3A-HDAC and 
the nucleosome-remodeling histone deacetylase (NuRD)-HDAC complexes, as well as 
Figure 1: Acetylation and 
Deacetylation of Histones 
The acetylated nucleosome shows 
histone tails that still have acetyl 
groups attached and are relaxed 
away from the nucleosome core.  
This relaxed formation makes it 
easier for transcription factors to 
bind (Hassig and Schreiber, 1997).  
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interaction with co-repressor Ying-Yang 1 (YY1) are a few examples (Ayer, 1999; Cress 
and Seto, 2000).  
 mSin3A was originally identified by its association with Mad-Max, a 
transcriptional repressor (Ayer, 1999).  mSin3A exists as the central part of a complex it 
forms with HDACs, with other proteins building from this complex to form a ‘core 
repressor complex’.  It has been shown that mSin3A will associate with HDAC1 and 2 in 
vivo to form a complex that will allow for repression of transcription by Mad-Max.  
However, mSin3A can suppress transcription without binding to HDACs (Cress and 
Seto, 2000).  A model has been developed termed the ‘targeted repression’ model which 
involves the mSin3A-HDAC complex being tied to a promoter by a transcriptional 
repressor, such as Mad-Max (Ayer, 1999).  Besides its association with Mad-Max, the 
mSin3A-HDAC complex also interacts with two other co-repressors SMRT and N-CoR, 
though there is no definitive information on the nature of that interaction.  
 HDACs 1 and 2 also interact with the NuRD-HDAC complex.  This complex 
does not contain any of the subunits of the mSin3A-HDAC complex (Ayer, 1999).  
Instead it associates with other proteins that assist in HDAC activity and chromatin-
remodeling activity.  There is a possibility that the co-repressor YY1 binds to HDACs 
and targets the NuRD complex.  YY1 is a repressor that negatively regulates transcription 
(Cress and Seto, 2000).  It can bind HDAC2 to DNA and this complex then acts as a 
repressor of transcription.  HDAC1 and 3 can also repress transcription when they are 
targeted to promoters of various repressors.  YY1 is expected to interact with various 
HDACs, but it has not been co-purified in complex at this point.     
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1.4 Inhibitors 
The information that HDACs are important in controlling gene expression has 
spiked interest in them as target sites for treatment of cancer, diabetes, obesity, 
inflammation, and neurodegenerative diseases.   
1.4.1 Areas for use 
Inhibitors that are developed for specific HDACs can be used as cancer treatment 
because they can cause cell arrest and reverse the transformations of some cells.  In 
certain types of cancer, tumor suppressor genes have been turned off or silenced.  HDAC 
inhibitors are able to target specific regulatory pathways and reactivate silenced 
suppressor genes (Cress and Seto, 2000).   
HDAC inhibitors are also of interest for diabetes, obesity, and inflammatory 
diseases research.  HDACs, specifically class I, have an effect on inflammation.  HDAC 
inhibitors appear to have an effect on a specific transcription factor, NF-κB, which 
reduces inflammatory mediator production (Blanchard and Chipoy, 2005).  Not only do 
HDAC inhibitors affect NF-κB, they also reduce cytokine and NO production, both of 
which contribute highly to inflammatory diseases.  HDAC inhibitors can act as both an 
activator of a pro-inflammatory gene or as a suppressor of pro-inflammatory genes based 
on its molecular target. 
1.4.2 Types 
Different HDAC inhibitors can act in millimolar concentrations while others are 
much more sensitive and can inhibit at nanomolar concentrations.  Currently all 
inhibition done on HDACs is reversible except for that done by trapoxin and depudesin, 
both of which are cyclic tetrapeptides (De Ruijter et al., 2003). 
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1.4.2.1 Short Chain Fatty Acids 
 The first discovered HDAC inhibitor was the short chain fatty acid, butyrate (Fig. 
2) (Hassig and Schreiber, 1997).   
Butyrate, in millimolar concentrations, inhibits both 
class I and class II HDACs, with the exception of 
HDAC6 and HDAC10 (Blanchard and Chipoy, 2005).  It 
can also have side effects on cell membrane, 
cytoskeleton, and other enzymatic activities.  
1.4.2.2 Hydroxamic acids 
Hydroxamic acids are a class of weak acids which includes Trychostatin A (TSA) 
(Fig. 3) and suberoylanilide hydroxamic acid (SAHA) (Fig. 4).  Currently the most potent 
inhibitor of HDACs is TSA which can inhibit HDACs in nanomolar concentrations. It 
was discovered to have proliferation-inhibitory properties with cancer cells making it an 
attractive drug candidate (De Ruijter et al., 2003).  However, TSA is a fermentation 
product of Streptomyces that takes many steps with a low yield making it costly and 
inefficient as a cancer therapeutic 
agent. 
 
 SAHA has also attracted a lot 
of attention as a possible inhibitor to 
be used in clinical work.  It has also 
recently finished being tested in Phase 
II clinical trials with positive results.  
(Wang et al., 2005)  SAHA is an 
 
Figure 2: Butyric acid structure  
 
Figure 3: Trychostatin A (TSA) structure (Vannini et 
al., 2004) 
 
Figure 4:  Suberoylanilide hydroxamic acid (SAHA) 
structure (Vannini et al., 2004) 
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inhibitor of both class I and class II HDACs in nanomolar amounts and inhibits by 
binding to the zinc-containing pockets of HDACs (Blanchard and Chipoy, 2005). 
 
1.4.2.3 Cyclic tetrapeptides/epoxides 
 Cyclic tetrapeptides are recognized by their complicated structure of a 12 atom 
cyclic tetrapeptide backbone as can be seen below (Hassig and Schreiber, 1997).  The 
structure also consists of various hydrophobic side chains that project out and can bind or 
disrupt interactions of HDACs with other proteins.  A current cyclic tetrapeptide that is 
being studied is apicidin (Fig. 5). 
Apicidin is a potent inhibitor that shows anti-
protozoal effects on certain parasites and anti-
proliferative effects on specific cancer cells 
(Kim, 2004).  Studies performed on its effects 
on various cancer cells established anti-
invasive and anti-angiogenic traits providing 
evidence that it may act as treatment for 
tumors and will be tested in phase I and II 
clinical trials.  
 
1.4.2.5 Benzamides  
 Benzamides are the final identified class of HDAC inhibitors.  MS-275 is an 
example of a benzamide inhibitor that has an affinity for HDAC1, but also inhibits 
HDACs 3 and 8 (Fig. 6) (Simonini et al., 2006). 
 
Figure 5: Apicidin structure (Vannini et al., 
2004) 
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MS-275 acts as a potent inhibitor 
of leukemia tumor cells in 
micromolar concentrations where 
it induces differentiation and 
apoptosis of cells.  It exists as a possible treatment and phase I clinical trials were 
recently completed establishing that there is a longer half-life than was expected from 
original trials and an optimum oral dose was determined (Minucci and Pelicci, 2006; 
Ryan et al., 2005).  
1.5 Goals 
 The goal of my research will be to assist in the cloning and production of both full 
length (FL) and catalytic or active domains (AD) of all class I HDACs in insect cells.  
Once expressed, each HDAC will be purified and then tested for activity using a 
commercial activity assay.  If the activity results are positive these proteins can be used 
for future research in the identification of unique inhibitor binding sites for individual 
HDACs.  To summarize the various steps of the research a flow chart was constructed 
(Fig. 7).  
 
 
Figure 6: MS-275 structure (Vannini et al., 2004) 
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Figure 7: Research Flow Chart 
A flow chart that depicts the 
multiple steps of obtaining the 
HDAC protein and testing 
activity 
Bacmid 
Virus 
Culture 
Purification 
Activity 
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2.0 Methodology: 
 
2.1 Virus Production 
 HDAC DNA was obtained in bacmid form from the Molecular Biology 
department at Blue Sky Biotech.  In total seven constructs were obtained, HDAC1 AD, 
1FL, 2AD, 3AD, 3FL, 8AD, and 8FL.  All full length constructs would produce a protein 
with molecular weight of around 50kD and the active domain constructs, a protein of 
roughly 30kD.   10µL of bacmid DNA was pipetted into 750µL of Opti-Mem, which is 
an ion free medium, and gently mixed.  45µL of Cell Fectin was pipetted into 750µL of 
Opti-Mem and gently mixed.  The two separate mixtures were allowed to rest for five 
minutes, followed by gentle mixing of the two.  This mixture was incubated at room 
temperature for 30 minutes.  The solution for each HDAC construct was then pipetted 
into 36mL of SF9 insect cells at a density of around 1.1 X 106 cells/mL.  The insect cell 
medium is HyQ SFX Insect Medium and is supplemented with 1mg/mL gentamycin.  
Cultures were grown at 27°C at 120rpm for five days.  The transfection was monitored 
by sampling on the fourth day.  A 1.5mL cell suspension sample was taken for each virus 
stock for western analysis, as well as a Cedex sample.  The Cedex provides cell counts, 
viability analysis, and information on the overall health of the cells, including cell 
diameter.  For information on the Cedex refer to the Innovatis website 
(http://www.innovatis.com).  When the viability had dropped below 70% and the cell size 
had begun to fall the virus was harvested by centrifugation at 1600 rpm for six minutes.  
The supernatant was then filtered through a 0.45 micron filter.  Standard fetal bovine 
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(Invitrogen) was added at a concentration of 3% to protect the virus for storage for 
extended periods of time.  The virus stocks were stored at 4° C.   
2.2 Viral Infections 
 To test the expression of the virus stocks in insect cells, three types of cells were 
used, SF21, SF9, and High 5.  All cultures are inoculated at a density of around 7.5 X 105 
cells/mL.  Cultures are allowed to grow for 24 hours at 27°C at 120rpm.  The media used 
for SF21 and High5 insect cells was Insect Express (Cambrex) and was supplemented 
with 1mg/mL gentamycin.  Media used for SF9 insect cells was HyQ SFX Insect 
Medium (Fisher) supplemented with 1mg/mL of gentamycin.  After the growth period of 
24 hours, cultures are infected with varying dilutions of the different virus stocks. 
For expression tests of HDAC3 AD and FL and HDAC2 AD 50mL SF21 insect 
cell cultures were infected with virus stocks at dilutions of 1:100, 1:1000, and 1:10000 
and allowed to grow for 72 hours.  Cedex and 1.5mL cell suspension samples were 
collected every 24 hours in each of the three dilutions, as well as from a control flask.  A 
separate expression test of HDAC1 AD, 1FL, and 8AD occurred in 250mL SF21 insect 
cell cultures infected with virus stocks at a dilution of 1:800.  Cultures were allowed to 
grow for 72 hours after which a 1.5mL cell suspension sample was taken.  A final 
expression test of the three different insect cell lines occurred.  50mL cultures of SF21, 
SF9, and High 5 insect cells were infected with the HDAC2 AD virus stock at a dilution 
of 1:2500.  Cultures were grown for 72 hours with 1.5mL cell suspension and Cedex 
samples being collected every 24 hours.  All cell suspension samples were analyzed on a 
12% polyacrylamide gel and a western blot was performed to measure expression. 
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 Using dilutions that would produce optimum expression in HDAC3 AD, 3FL, 
2AD, and 8FL 800mL cultures of SF21 insect cells were infected with the different virus 
stocks.  For HDAC3 AD this was a dilution of 1:5000, 3FL was 1:5000, 2AD was 
1:5500, and 8FL was 1:800.  All of the cultures were grown and sampled as previously 
described.  When the cells had reached optimum expression where the viability had 
begun to dip and the cell size was high, around 72 hours, the cultures were harvested and 
a 1.5mL cell suspension sample was collected.  The cultures were centrifuged at 2500rpm 
for 15 minutes and were re-suspended and washed with 1X phosphate buffered saline 
(PBS) and transferred to 50mL conical tubes and centrifuged again at 2500rpm for 15 
minutes.  Cell suspension samples were analyzed using a 12% polyacrylamide gel and a 
western blot.   
2.3 Purification 
The cell pellet, roughly 8.0 grams, obtained from the expression runs was 
weighed and 200µL of protease inhibitor cocktail (PIC) (American Bioanalytical) was 
added.  The pellet was then resuspended in 40mL of 1X ‘WX’.  ‘WX’ is a proprietary 
lysis buffer of Blue Sky Biotech.  The resuspended cells were then lysed by sonication 
three times for 30 seconds on ice with a one to two minute period in-between for the 
sample to cool.  After sonication the sample was centrifuged at 15,000 rpm for 30 
minutes.  A 5mL pre-charged Ni Sepharose 6 Fast Flow column (Amersham Biosciences) 
was prepped by adding 5mL of 1X WX three times to the column to clean it and adjust it 
for the buffer that will be used.  The supernatant is loaded on the column.  The column 
was then washed two times with 5mL of 1X WX with 20mM imidazole.  The column 
was eluted twice with 3mL of 1X WX and 300mM imidazole.  Finally the column is 
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stripped using 5mL of 1X WX and 500mM imidazole.  Western blot and coomassie stain 
were used to analyze the 1.5mL samples collected from the whole cell, flow through, 
wash, each elution, and strip. 
2.4 Protein Gels and Western Blots 
All cell suspension samples collected were analyzed using 12% SDS-Page 
polyacrylamide gel (Sambrook and Russell, 2001) and then performing a western transfer 
onto 0.45 micron nitrocellulose membrane (Pierce Biotechnology Inc.).  Each cell 
suspension sample was first centrifuged at 14000rpm for five minutes.  The supernatant 
was then discarded and the cell pellet was prepped using 200µL of Cytobuster (Novagen) 
and 0.25µL of PIC to bust open the cells and release the protein.  The mixture was then 
placed on an orbital vortexer for 20 minutes after which a 50µL cell suspension sample 
was combined with 150µL dH2O and 100µL SDS-Page loading dye and labeled the 
whole cell fraction.  The resuspended cells were then centrifuged at 14000rpm for 10 
minutes to spin down cell debris.  A 100µL sample was collected from the supernatant 
and combined with 100µL dH2O and 100µL SDS-Page loading dye and labeled the 
soluble fraction.  The whole cell and soluble fractions were boiled on a heating block for 
5 minutes, allowed to cool, and then run on a 12% gel and a western transfer was 
performed. 
After the transfer is completed the membrane is blocked with a 5% milk solution 
using 1X tris buffered saline-tween (TBST) for 30 minutes and then placed in a solution 
of 1:1000 anti-His primary antibody (Molecular Probes) overnight at 4° C.  The western 
is then washed three times for five minutes each with 1X TBST and placed in a solution 
of 1:2000 anti-mouse AP secondary antibody (Promega) for four hours.  It was then 
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washed three times again with 1X TBST and is developed using Western Blue developer 
(Promega).    
2.5 Protein Concentration  
 To measure the concentration of protein obtained through purification a 
bicinchoninic acid (BCA) assay was performed.  The assay kit (Pierce) provides a protein 
standard and a developing buffer.  First different concentrations of the protein standard 
are prepared at 0, 0.2, 0.4, 0.6, 0.8, and 1.0 µg/mL.  The HDAC samples are prepared in 
three separate dilutions of 100% HDAC sample, a 50% HDAC sample, and a 20% 
HDAC sample.  All dilutions were prepared using purified water.  All samples were run 
in triplicate.  When loading the samples into a 96-well plate 20µL of protein sample was 
added with 200µL of the developing buffer and thoroughly mixed.  The plate was 
allowed to incubate at 37° for 30 minutes.  After the incubation period the plate is 
allowed to cool to room temperature and then read using a microplate reader at 570nm 
and the data is graphed.   
2.6 Activity Assay 
 An activity kit (Epigentek) that uses colorimetric detection to measure 
deacetylation was used.  The assay kit obtained provides 8-well strips.  The wells are first 
washed with 150µL of 1X wash buffer.  Then 50µL of a biotinylated HDAC substrate is 
added to each well and incubated at room temperature for 45 minutes during which time 
the biotinylated substrate will bind to the well.  The wells are then washed twice with 
150µL wash buffer to remove excess substrate.  After washing, 28µL of assay buffer and 
2µL of the HDACs were added to the wells and allowed to incubate at 37° for 60 
minutes.  The kit provided TSA as an inhibitor.  The wells are washed with 150µL wash 
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buffer after the incubation period and 50µL capture antibody is added and incubated on a 
rocking platform for 60 minutes at 100rpm.  Another wash occurs and 50µL detection 
antibody is added and incubated for 30 minutes at room temperature.  There is one final 
wash phase that consists of four washes with 150µL and 100µL of the developing 
solution is added.  It is allowed to develop for up to 10 minutes away from light and the 
development progress can be monitored by the amount of blue that appears in each well.  
After 10 minutes 50µL of stop solution is added and the plate can be read on a microplate 
reader at 450nm and charted graphically.  Blank wells with no substrate or HDAC and 
control wells of only substrate are also assayed.  In addition, an active HDAC (UpState) 
was used as a positive control.   
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3.0 Results: 
3.1 Virus Production 
 Using previously constructed and verified clones of HDAC 3FL, 3AD, and 2AD 
viral stocks were produced by transforming SF9 insect cells with bacmid DNA. 
 
 
All transfections were monitored on westerns using whole cell lysates and soluble 
fractions from lysed cells.  Each transfection showed expression for the corresponding 
HDAC (Fig. 8) so the viruses that were harvested from these cells were then used for 
subsequent expression testing and scale-ups.  Expression in the soluble fraction is weaker 
than that in the whole cell most likely due to some of the protein remaining in the cell 
fragments after lysing.   
3.2 Expression Test 
 For this set of viral stocks an expression test was performed.  Each viral HDAC 
construct was used to infect 50mL SF21 insect cell cultures in dilutions of 1:100, 1:1000, 
and 1:10000.  The cultures were allowed to grow for 72 hours with samples being taken 
every 24 hours (Fig. 9). 
Figure 8: HDAC Expression during 
Viral Stock Production 
Western blot of HDAC2 AD, 3AD, 
and 3FL viral stocks produced in SF9 
insect cells.  Arrows represent the 
expected size of the HDAC protein.  
WC: whole cell, SF: soluble fraction 
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A.  
B.  
C.  
 
 
 
There appears to be some expression for each construct.  Expression is 
significantly higher in the whole cell samples, but it is not uncommon for protein levels 
to be significantly lower in the soluble fraction. 
Figure 9: HDAC Expression 
Tests 
Western blots for different 
HDAC constructs with data for 
every 24 hours at dilutions of 
1:100, 1:1000, and 1:10000 in 
both whole cell (WC) and 
soluble (SF) fragments.  
HDAC2 AD expression (A), 
HDAC3 AD expression (B), 
and HDAC3 FL expression 
(C).  Arrows represent 
expected protein size. 
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When comparing the westerns from the transfected cells with those of the 
expression tests, the transfected cells appear to have better expression of the HDAC 
protein.  To determine if this was due to differences in the insect cell lines a test was run 
of a single dilution of 1:2500 of HDAC2 AD in SF9, SF21, and High-5 cells over a 
period of 72 hours.  HDAC2 AD was chosen because it had showed strong expression in 
SF9 insect cells and faint expression in SF21s. 
 
 
 
 The results (Fig. 10) appear to show that there is no discernable difference 
between expression levels in the different cell lines.  These westerns also verified 
expression of HDAC2 AD which had shown faint expression in the expression test.   
 Additionally an expression test was done for HDAC constructs already in P1 virus 
stocks, HDACs 1AD, 1FL, and 8AD.  Cultures were grown in a 250mL volume of SF21 
insect cells and infected at a dilution of 1:800 for each virus stock.  
 
Figure 10: Insect Cell 
Expression Test 
Western blot of HDAC2 
AD in SF21, SF9, and 
High-5 insect cells at a 
dilution of 1:2500 with 
data from 24 hour 
intervals.  Arrow 
represents expected 
protein size. 
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Figure 11 verifies the expression of HDACs 1AD, 1FL, and 8AD in SF21 insect cells.   
3.3 Expression (Large Scale) 
Using the data obtained from the expression tests, larger scale infections were 
performed in 800mL volume.  In addition to scaling up HDACs 2AD, 3AD, and 3FL, 
HDAC8 FL was also run.  HDAC2 AD was infected at a dilution of 1:5500, 3AD was 
infected at a dilution of 1:5000, 3FL at a dilution of 1:5000, and 8FL was infected at 
1:800.  After 72 hours the cells were harvested and tested for presence of the HDAC 
protein (Fig. 12).  
      
 
The western results are not conclusive.  However, the information obtained from the 
Cedex appears to confirm that the cells were infected, so it is possible that the cells are 
expressing the HDAC protein and it is not highly visible because the antibody did not 
Figure 11: HDAC1 AD, 1FL, 
and 8AD Expression Test 
Western blot that verifies 
expression of HDAC8 AD, 1FL, 
and 1AD in SF21 insect cells in 
both whole cell and soluble 
fractions. 
Figure 12: HDAC Scale-
Ups 
Western blot for HDAC2 
AD, 3FL, 8FL, and 3AD 
800mL scale-ups in SF21 
insect cells. 
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bind.   Following this reasoning the harvested cells were used in further protein 
purification stages. 
3.4 Purification 
 Each HDAC construct included an N’ terminal polyhistitidine tag to allow for 
purification on a Ni column.  HDACs 2AD, 3AD, 3FL, and 8FL were all extracted from 
the large scale infections and subjected to column chromatography.  Samples were 
collected throughout the purification and analyzed by coomassie stain and western 
blotting (Fig. 13).  
A.  B.  
 
C. D.  
Figure 13: HDAC Purification Results 
Coomassie stains (A, B) and western blots (C, D) that show the results of the HDAC 
purification.  Samples collected from whole cell (WC), flow through (FT), wash, 
elution 1 (E1), elution 2 (E2), and strip were analyzed for each HDAC construct.  
HDAC3 FL purification (A, C), HDAC3 AD purification (A, D), HDAC2 AD 
purification (B, C) and HDAC8 FL purificatoin (B, D). 
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The western results appear positive for HDAC8 FL and HDAC3 FL, but not necessarily 
for HDAC2 AD and 3AD.  Using the elution 1 samples collected, protein concentrations 
were calculated using the BCA assay. 
3.5 Activity Assay 
 Using the protein concentrations obtained from the BCA assay 100ng and 2500ng 
HDAC samples were prepared for use in a commercially purchased HDAC activity 
assay.  For the first test of the assay these samples were run in duplicate along with 
substrate only and a commercial source of active HDAC8.  In addition to the purified 
proteins mentioned previously, the activity of other purified proteins, HDACs 1AD, 1FL, 
8AD, and 8FL was also tested (Fig. 14).   
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Figure 14: Activity Assay Using Two Concentrations 
Each sample was run in duplicate and an average of the two readings is plotted.  HDACs were tested 
in 100ng and 2500ng samples.  The HDAC proteins obtained through purification were tested 
against substrate only and an active HDAC8 available commercially (8AC).  HDAC samples marked 
with a ‘*’ were produced previously and also tested in this assay. 
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Deacetylation of the biotinylated substrate will result in a decrease in OD.  It appears that 
all HDACs, except the commercially purchased HDAC8, have deacetylation activity.  
This is more obvious in the samples that are treated with the higher concentration of 
HDAC.  The commercially purchased HDAC, which is supposed to be active, does not 
appear to be active in this assay.  
To determine if the deacetylation observed in the first assay was due to HDACs 
the assay was repeated using the higher concentration of purified protein and a specific 
inhibitor, TSA.  This should show substantial reduction in deacetylation if it is indeed due 
to HDAC activity (Fig. 15). 
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Figure 15: Activity Assay w/ Inhibitor 
Data obtained from the activity assay is charted graphically with HDACs without an 
inhibitor and with an inhibitor.  Samples were run in duplicate and the average was taken 
for analysis.   
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 Again the commercially purchased HDAC8 does not appear to be active in this 
assay as there is no significant reduction in signal upon its addition.  Additionally, 
although the other HDACs appear to be active in this assay, there is no inhibition by 
TSA.  The TSA is present in 200X molar excess if it is assumed the protein is 100% 
HDAC.  This should be enough to inhibit all HDAC activity.  The odd data for HDAC1 
FL may be due to an abnormal sample that was significantly higher OD then its duplicate 
without inhibitor, the OD readings of the duplicate samples were 0.972 and 0.523. 
 This assay was repeated (Fig. 16).  The major difference in this assay is that the 
purchased HDAC8 appears to show some minimal activity with less than 50% of the 
signal compared to the substrate alone.  However, this activity is not inhibited by TSA.  
Only one sample, 1FL, shows a decrease in deacetylation when the inhibitor is added, but 
it is not clear if this is a significant, particularly as it is contrary to the previous data. 
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Because of lack of materials only one more assay was able to be performed.  The 
final assay repeats the first assay by testing the HDACs in two separate concentrations, 
this time using 1000ng and 2500ng samples (Fig. 17).   
Figure 16: Activity Assay w/ Inhibitor 
Data obtained from the activity assay is displayed graphically for HDAC 
constructs with both an inhibitor and no inhibitor.  All samples were run in 
duplicate and the average is being used for analysis. 
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For several samples, 8FL, 1AD, 1FL, 8FL, there is a clear difference between the two 
concentrations.  For several others, 2AD, 3FL, 3AD, 8AD, the OD is very low and not 
significantly changed by increasing the protein concentration.  This suggests that even the 
lower concentration has saturated the system.  In general these are the active domain 
constructs.  Since they are smaller, the same amount of protein would be expected to 
have a higher concentration of enzyme.  However, since the protein samples were not 
purely active domain constructs it is difficult to extrapolate activity analysis from this 
data.  
Figure 17: Activity Assay Using Two Concentrations 
Data obtained from the activity assay is plotted graphically to display these differences.  
All samples are run in duplicate and the average is taken for analysis.   
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4.0 Discussion: 
 Histone deacetylases have become a target area for research in many scientific 
fields, particularly cancer.  To perform the large amount of research on HDACs that is 
currently occurring it is important to find a way to produce them in bulk.  The ability to 
express class I HDACs in insect cells appears to be a viable option.  Not only were full 
length HDACs expressed, but predicted catalytic or active domains of HDACs were also 
expressed.  To be able to show expression of possible active domain HDACs is also 
important in the understanding of the possible structure of this area. 
There is a definite variation in expression levels between the different HDAC 
constructs.  One way to separate the data is between the full length and the active 
domains.  The active domain constructs appear to have a lower expression level than the 
full length versions.  This could be due to a decrease in stability.   
 An important part of obtaining the HDAC proteins was to verify that they were 
active.  Inactive HDACs would not be beneficial for clinical research.  To test the activity 
an activity assay was performed.  The assay measured the acetylated substrate via a 
colorimetric assay.  Thus, the lower the average OD value for each HDAC construct, the 
more active that HDAC would appear to be.  Unfortunately, the results of the activity 
assay are not conclusive for HDAC activity.  Although the purified HDAC samples all 
showed some activity in the assay, none of them were inhibited by TSA, a specific 
HDAC inhibitor.  It is possible there was no inhibition because the TSA was inactive.  
However, there is no way to determine if this is true based on the data.  A commercially 
purchased, and supposedly active HDAC8, also showed no significant activity in this 
assay.  If this enzyme showed activity it could have been used to show the efficiency of 
 33 
the inhibitor.  However, because it showed no activity there was no way to determine if 
the inhibitor was active.  Thus, this data only demonstrates that the purified protein 
samples, which all clearly have multiple proteins, do contain an enzymatic activity that 
can deacetylate the substrate in the assay.  Further experiments must be done to 
demonstrate that the activity present in the assay is in fact due to the cloned HDACs.     
 At the end of the testing all HDAC constructs had been expressed, purified, and 
activity tested except for one.  A summary of the various steps can be seen in Table 2. 
Construct Cloned Expressed Purified Activity Active 
1AD X X X X Yes 
1FL X X X X Yes 
2AD X X X X Yes 
2FL           
3AD X X X X Yes 
3FL X X X X Yes 
8AD X X X X Yes 
8FL X X X X Yes 
 
Figure 18: Summary of Completion 
Although all the constructs that were tested for activity appeared to be active there were 
varying degrees of activity.  If another activity assay was purchased then it could be 
attempted to determine actual activity values.  Also, it would be beneficial to test more 
concentrations of HDACs, in particular HDAC3, to better view the differences between 
active domains and full length domains.  In addition to measuring actual activity values 
an attempt at cloning HDAC2 FL could also be performed to continue this research.  
Finally, to better examine the inhibitor data, an active inhibitor should be purchased from 
a separate source and used when repeating the activity assay.   
The ability to produce HDACs in a cost effective manor is important because of 
the amount of research that is currently being conducted using these enzymes.  However, 
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being able to express class I HDACs in insect cells is not the only thing provided here.  
Expression of possible active domain constructs for class I HDAC has also been 
established.  This data can be used in further studies in the understanding of what makes 
each HDAC unique.  If unique domains for each HDAC can be identified, then the 
development of inhibitors that are specifically designed for those domains becomes a 
possibility.  By creating HDAC specific inhibitors a better understanding can begin of 
what each HDACs role is and what the effects are of inhibiting it.  This data can be 
applied to developing treatments for specific cancers or other diseases where HDACs 
play a role. 
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Data Run Sheet 1: HDAC2 AD #2 Virus Generation 
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Data Run Sheet 2: HDAC2 AD #3 Virus Generation 
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Data Run Sheet 3: HDAC3 FL #5 Virus Generation 
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Data Run Sheet 4: HDAC3 AD #8 Virus Generation
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Data Run Sheet 5: HDAC2 AD Expression Scout - Control 
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Data Run Sheet 6: HDAC2 AD Expression Scout - 1:100 
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Data Run Sheet 7: HDAC2 AD Expression Scout - 1:1000 
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Data Run Sheet 8: HDAC2 AD Expression Scout - 1:10k 
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Data Run Sheet 9: HDAC3 AD Expression Scout - 1:100 
 46 
 
Data Run Sheet 10: HDAC3 AD Expression Scout - 1:1000 
 47 
 
Data Run Sheet 11: HDAC3 AD Expression Scout - 1:10k 
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Data Run Sheet 12: HDAC3 FL Expression Scout - 1:100 
 49 
 
Data Run Sheet 13: HDAC3 FL Expression Scout - 1:1000 
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Data Run Sheet 14: HDAC3 FL Expression Scout - 1:10k 
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Data Run Sheet 15: HDAC2 AD Expression Test - SF9 Control 
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Data Run Sheet 16: HDAC2 AD Expression Test - SF9 1:2500 
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Data Run Sheet 17: HDAC2 AD Expression Test - SF21 Control 
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Data Run Sheet 18: HDAC2 AD Expression Test - SF21 1:2500 
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Data Run Sheet 19: HDAC2 AD Expression Test - Hi-5 Control 
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Data Run Sheet 20: HDAC2 AD Expression Test - Hi-5 1:2500 
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Data Run Sheet 21: HDAC3 FL 800mL Scale-Up 
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Data Run Sheet 22: HDAC2 AD 800mL Scale-Up 
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Data Run Sheet 23: HDAC3 AD 800mL Scale-Up 
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Data Run Sheet 24: HDAC8 FL 800mL Scale-Up 
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Data Run Sheet 25: HDAC3 AD 800mL Scale-Up (Repeat) 
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Data Run Sheet 26: HDAC8 FL 800mL Scale-Up (Repeat) 
 
 
